COMPANY RESEARCHAstraZeneca is a United Kingdom-based, science-led pharmaceutical company engaged in discovering, developing and commercializing prescription medicines. Its research and business span oncology, biopharmaceutical medicines and rare diseases, using several treatment technologies and discovery platforms. The company reports its activities through an official corporate and investor website rather than maintaining a fixed product catalogue in this directory. Its investor FAQ confirms the AZN symbol across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange, which are securities of the same corporate issuer.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
AstraZeneca is a United Kingdom-based, science-led pharmaceutical company engaged in discovering, developing and commercializing prescription medicines. Its research and business span oncology, biopharmaceutical medicines and rare diseases, using several treatment technologies and discovery platforms. The company reports its activities through an official corporate and investor website rather than maintaining a fixed product catalogue in this directory. Its investor FAQ confirms the AZN symbol across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange, which are securities of the same corporate issuer.
LSE: AZN Nasdaq Stockholm: AZN NYSE: AZN
small-molecule · biologics · oncology-therapeutics
oncology · cardiovascular · respiratory · immunology · rare-diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| AZ–Syneron oral macrocycle research | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 1 / 1 related items
Syneron Bio reported nearly $100 million raised across its Series A and A+ rounds, with participation from AstraZeneca and multiple strategic and venture investors. Proceeds support its Synova high-throughput macrocyclic peptide discovery platform and advancement of pipeline programs toward clinical development. The combined financing amount is not a single round, and candidate-level oral clinical data were not disclosed.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.